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Type	 1	 diabetes	 is	 an	 autoimmune	 disease	 resulting	 from	 the	 destruction	 of	 pancreatic-β	27	
cells	by	the	immune	system	involving	innate	and	adaptive	immune	cells.	Mucosal-associated	28	
invariant	 T	 (MAIT)	 cells	 are	 innate-like	 T-cells	 recognizing	 bacterial	 riboflavin-precursor	29	
derivatives	presented	by	the	MHC-I	related	molecule,	MR1.	Since	T1D	is	associated	with	gut	30	
microbiota	modification,	we	 investigated	MAIT	cells	 in	 this	pathology.	 In	T1D	patients	and	31	
non-obese	 (NOD)	 diabetic	 mice,	 we	 detected	 MAIT	 cell	 alterations,	 including	 increased	32	
granzyme	B	production,	which	occur	before	disease	onset.	Analysis	of	NOD	mice	deficient	33	
for	MR1,	and	therefore	lacking	MAIT	cells,	revealed	a	loss	of	gut	integrity,	increased	anti-islet	34	
responses	 associated	with	 exacerbated	 diabetes.	 Altogether	 our	 data	 highlight	 the	 role	 of	35	
MAIT	 cells	 in	 the	 maintenance	 of	 gut	 integrity	 and	 the	 control	 of	 anti-islet	 autoimmune	36	













physiopathology	 of	 T1D	 involves	 both	 innate	 and	 adaptive	 immune	 systems	 that	 are	46	
inappropriately	 activated	 inducing	 a	 loss	 of	 self-tolerance	 and	 islet	 destruction
2–5
.	 T1D	 is	47	
characterized	 by	 the	 presence	 of	 anti-islet	 autoantibodies	 and	 autoreactive	 T	 cells.	 Innate	48	
immune	cells	are	involved	at	various	stages	of	the	disease	and	are	particularly	important	for	49	
the	 initiation	 of	 the	 local	 immune	 response	 in	 the	 pancreas	 and	 the	 pancreatic	 lymph	50	
nodes










MAIT	 cells	 are	 innate-like	 T	 cells	 recognizing	 bacterial	 metabolites,	 derived	 from	 the	55	







with	 a	 restricted	 set	 of	 TCRβ	 chains.	MAIT	 cells	 produce	 various	 cytokines	 such	 as	 TNF-α,	59	
IFN-γ,	 IL-17	 and	 granzyme	 B	 (GzB)	 that	 could	 participate	 to	 tissue	 inflammation	 and	 cell	60	
death
18,21–31
.	 The	near	 absence	of	MAIT	 cells	 in	 germ-free	mice
18,32
	 and	 their	 physiological	61	
localization	 at	 mucosal	 sites	 including	 the	 gut
18,23
	 suggest	 a	 strong	 interaction	 with	 the	62	
microbiota.	Here	for	the	first	time	we	described	MAIT	cell	alteration	in	T1D	patients	and	our	63	
mouse	 data	 reveal	 the	 protective	 role	 of	MAIT	 cells	 against	 T1D.	 The	 localization	 and	 the	64	







phenotype	 in	 fresh	 peripheral	 blood	 samples	 from	 children	 with	 recent	 onset	 T1D	 and	72	
children	with	established	T1D	as	compared	to	age-matched	control	children	(Supplementary	73	




and	number	was	decreased	 (3-fold)	 in	 the	blood	of	 recent	onset	T1D	children	whereas	no	76	




	 and	 double	 negative	 (DN)	MAIT	 cell	 subsets	 (Supplementary	 Fig.	 1b).	 Of	 note	79	






MAIT	 cell	 frequency	 at	 the	 onset	 of	 T1D	 was	 not	 secondary	 to	 changes	 in	 other	 T	 cell	82	
populations	 nor	 to	 down-regulation	 of	 the	 CD161	 marker	 (Supplementary	 Fig.	 2a-b).	83	
Analysis	 of	MAIT	 cell	 phenotype	 showed	 a	 decreased	 frequency	 of	MAIT	 cells	 expressing	84	
tissue	 recruitment/adhesion	 molecules	 (CCR6,	 CD56)	 at	 the	 onset	 of	 the	 disease,	 an	85	
increased	 frequency	of	MAIT	 cells	 expressing	 the	activation/exhaustion	markers	CD25	and	86	
PD1,	and	a	decreased	frequency	of	MAIT	cells	expressing	the	anti-apoptotic	molecule	Bcl-2	87	








with	 the	 frequency	 of	 MAIT	 cells,	 whereas	 MAIT	 cell	 CD25	 expression	 was	 negatively	92	






stimulation.	MAIT	 cells	 from	children	with	 recent	onset	 T1D	produced	 less	 IFN-γ,	whereas	99	
their	production	of	TNF-α,	 IL-4,	 and	GzB	was	 increased	as	 compared	with	MAIT	cells	 from	100	
control	children	(Fig.	2a-b).	Of	note,	among	these	effector	molecules	only	the	frequency	of	101	
GzB	correlated	with	the	frequency	of	MAIT	cells,	the	higher	GzB	production	was	observed	in	102	
patients	 with	 the	 lower	 frequency	 of	 MAIT	 cells	 (Supplementary	 Fig.4).	 Multi-parametric	103	
analysis	of	cytokines	and	GzB	production	by	MAIT	cells	also	showed	an	intermediate	status	104	
of	blood	MAIT	cells	from	children	with	established	T1D,	between	those	from	control	children	105	





CD25	activation	markers.	Addition	of	 blocking	MR1	mAb	 confirms	 that	 this	 activation	was	109	
TCR-dependent.	Interestingly,	MAIT	cell	activation	was	significantly	reduced	in	children	with	110	






and	2).	 Interestingly,	 the	 frequency	of	GzB
+









2	 expression,	 were	 also	 associated	 with	 the	 age	 at	 diagnosis	 (Supplementary	 Fig.	 5).	 No	122	
significant	 correlations	 between	MAIT	 cell	 parameters	 and	 age	were	 observed	 in	 controls	123	
and	 children	 with	 established	 T1D	 (data	 not	 shown).	 Production	 of	 GzB	 by	 MAIT	 cells	124	






The	 strong	 inverse	 correlation	 between	GzB	 production	 by	MAIT	 cells	 and	 the	 age	 of	 the	129	
children	 at	 the	 time	 of	 onset	 suggested	 that	MAIT	 cells	 could	 participate	 to	 β-cell	 death.	130	
Interestingly,	 inflammatory	 cytokines	 usually	 produced	 in	 inflamed	 islets	 during	 T1D	131	


































,	 and	 to	 some	 extent	 GzB
+
,	 MAIT	 cells	 decreased	 to	 levels	 observed	 in	 the	148	
control	 children	 (Fig.	 4a).	 This	 longitudinal	 analysis	 strengthened	 the	data	obtained	 in	 the	149	






Canonical	analysis	was	performed	 to	compare	MAIT	cell	 alterations	 in	 the	 three	groups	of	154	
children	(controls,	 recent	onset	and	established	T1D).	This	analysis	revealed	that	MAIT	cell	155	




Importantly,	we	 confirmed	 in	 another	 cohort	 of	 children	 from	Milano	 that	 frequency	 and	160	
phenotype	alteration	of	MAIT	 cell	was	observed	 in	 recent	onset	T1D	as	 compared	 to	age-161	
matched	 control	 children	 (Supplementary	 Table	 3	 and	 supplementary	 Fig.	 7).	 However	162	
technical	difficulties	impacting	CD56	analysis	on	these	frozen	cells	did	not	allow	to	applying	163	
the	predictive	model.	164	
Finally,	 to	 test	 whether	 MAIT	 cell	 alterations	 could	 be	 detected	 before	 the	 onset	 of	165	
diagnosis,	 we	 characterized	MAIT	 cells	 in	 adults	 at	 risk	 to	 develop	 T1D	 defined	 as	 direct	166	
relatives	of	T1D	patients	with	at	least	two	positive	autoantibodies	(Supplementary	Table	4).	167	








of	 individuals	analyzed	were	 limited	 (Fig.	4d).	Altogether	our	data	 in	patients	 suggest	 that	170	
MAIT	cells	represent	a	new	biomarker	in	T1D	and	they	could	play	a	role	in	the	pathogenesis	171	








,	 thus	we	 investigated	whether	 any	 of	 the	MAIT	 cell	 alterations	178	
observed	 in	T1D	patients	were	evident	 in	 this	model.	MAIT	cells	were	characterized,	 in	10	179	
week-old	NOD	 and	 C57BL/6	mice,	 using	mouse-MR1	 tetramers	 loaded	with	 the	 riboflavin	180	







(PLN).	However	MAIT	 cells	were	 present	 in	 pancreatic	 islets	 of	NOD	mice	 and	were	more	184	



















strong	 producers	 of	 IL-17A	 and	 TNF-α,	whereas	 IFN-γ	 and	 IL-22	was	 detected	 in	 only	 few	196	
cells	 (Fig.	5g-h	and	supplementary	Fig.	10).	Moreover,	a	majority	of	MAIT	cells	 in	PLN	and	197	
ileum	 from	 NOD	 mice	 express	 CD44	 and	 they	 produce	 large	 amount	 of	 cytokines.	198	
Interestingly,	similar	results	were	obtained	for	TNF-α,	IFN-γ	and	IL-22	cytokine	production	in	199	
both	C57BL/6	and	NOD	mice	(Fig.	5h	and	supplementary	Fig.	11).	Of	note,	higher	frequency	200	












We	next	 analyzed	MAIT	 cells	 in	NOD	mice,	 at	 three	 stages	 of	 disease	 development,	 early	209	
stage	(6-7	weeks	old),	pre-diabetic	 (15-17	weeks	old)	and	mice	at	the	onset	of	the	disease	210	
(Fig.	6a).	These	 three	stages	correspond	respectively	 to	mild	peri-insulitis	 characterized	by	211	
moderate	infiltration	of	inflammatory	cells	around	pancreatic	islets,	to	insulitis	associated	to	212	










disease	 development.	 Interestingly	 there	 is	 a	 higher	 recruitment	 of	 MAIT	 cells	 in	 the	219	
pancreas	 of	 20-25	 week	 old	 NOD	 mice	 than	 in	 younger	 (8-10	 week)	 mice	 (Fig.	 6	 b).	 In	220	








and	 further	 increased	 in	diabetic	mice	 (Fig.	6c).	Both	GzB	and	 IFN-γ	 from	MAIT	cells	 could	229	
participate	to	pancreatic	β-cell	death4.	This	 increased	production	of	 IFN-γ	and	GzB	 in	 islets	230	















cytokine	 inducing	 the	 production	 of	 these	 cytokines.	 Interestingly,	 at	 diabetes	 onset	 IL-23	244	






To	 investigate	 whether	 gut	 microbiota	 could	 directly	 impact	 MAIT	 cell	 function,	 we	249	
measured	at	different	stages	of	disease	development	the	level	of	bacterial	agonist	ligand	in	250	
intestinal	 content	 using	 an	 in	 vitro	 biological	 assay	 (Fig.	 7d-g).	 Intestinal	 contents	 activate	251	
purified	MAIT	cells	is	a	dose	dependent	manner,	as	5-OP-RU	positive	control	(Fig.	7d-e).	This	252	
activation	 was	 MR1	 specific	 since	 it	 was	 inhibited	 by	 the	 addition	 of	 Ac-6-FP	 antagonist	253	
ligand	 (Fig.	 7d-f).	MAIT	 cell	 activation	 by	 intestinal	 contents	 from	 young,	 pre-diabetic	 and	254	
diabetic	NOD	mice	did	not	reveal	significant	modification	of	MAIT	cell	 ligand	concentration	255	
(Fig.	7g).	Altogether,	these	data	suggest	that	MAIT	cell	defective	IL-17	and	IL-22	production	256	


















mice	 lacked	MAIT	 cells,	whereas	 there	were	no	 significant	differences	 in	 the	 frequency	of	265	
Foxp3
+
	 CD4	 Treg,	 iNKT	 and	 γδT	 cells	 in	 the	 spleen	 and	 PLN	 from	 both	 lines	 (Fig.	 8a	 and	266	
supplementary	 Fig.	 13).	 Most	 interestingly,	 MR1
-/-
	 NOD	 mice	 developed	 exacerbated	267	
diabetes	 compared	 to	 their	 littermate	MR1
+/-
	 controls	 indicating	a	protective	 role	of	MAIT	268	









































MHC	class	 II	molecules	and	CD86	reflecting	 their	more	activated	status	 (Fig.	8e).	Since	gut	280	
mucosa	 integrity	 controls	 immune	 cell	 activation
44,51,52











the	role	of	MAIT	cells	 in	 the	control	of	gut	 integrity	and	DC	priming	 in	 the	PLN,	significant	288	








This	 study	 reveals	MAIT	 cell	 alteration	 in	 T1D	 patients	 as	well	 as	 in	 NOD	mice.	MAIT	 cell	295	
frequency	 is	 lower	 in	 the	peripheral	blood	of	patients	 compared	 to	healthy	 children.	 Such	296	




their	 increased	 frequency	 and	 migration	 in	 the	 pancreas	 of	 NOD	 mice	 during	 T1D	299	
development.	 Lower	 frequency	 of	 blood	MAIT	 cells	 could	 also	 result	 from	 their	 sustained	300	
activation	leading	to	cell	exhaustion	as	indicated	by	their	expression	of	Bcl-2,	CD25	and	PD1	301	
and	 by	 their	 defective	 in	 vitro	 response	 to	 Ag	 specific	 stimulation,	 in	 contrast	 to	 their	302	
increased	cytokines	and	GzB	production	upon	PMA-ionomycin.	Of	note	MAIT	cell	defect	 in	303	
T1D	 might	 not	 only	 be	 a	 consequence	 of	 diabetes	 development	 but	 also	 might	 reflect	304	
intrinsic	differences.	Indeed	in	NOD	mice,	as	compared	to	C57BL/6	mice,	MAIT	cells	are	less	305	
frequent	and	express	a	less	mature	phenotype,	based	on	CD44	expression.		306	
Our	 study	 in	 NOD	 mice	 points	 out	 the	 different	 phenotype	 and	 function	 of	 MAIT	 cells	307	
according	 to	 their	 tissue	 localization.	 This	 heterogeneity	 of	 MAIT	 cells	 observed	 in	 mice	308	
11	
	




The	 analysis	 of	 peripheral	 tissues	 from	NOD	mice	 highlights	 the	 role	 of	MAIT	 cells	 in	 two	313	
tissues,	 the	 pancreas	 and	 the	 gut	mucosa.	 In	 the	 pancreas,	 not	 only	MAIT	 cell	 frequency	314	







cells	 express	 the	 highest	 level	 of	 GzB.	 This	 parameter	 has	 the	 strongest	 correlations	with	318	
clinical	characteristics,	age	at	diagnosis	and	%	of	HbA1c.	Of	note,	increased	GzB	production	319	
was	 not	 observed	 in	 other	 T	 cell	 populations	 (data	 not	 shown).	 Moreover	 co-culture	320	
experiments	show	that	MAIT	cells	are	able	to	directly	kill	human	β	cell	line.		321	
In	 contrast	 to	 the	 pancreas,	 in	 the	 gut	 mucosa	 MAIT	 cells	 might	 play	 a	 protective	 role	322	
through	 their	 production	 of	 IL-17A	 and	 IL-22,	 two	 key	 cytokines	 in	 intestinal	323	
homeostasis
41,42,56,57





FITC-dextran	 assay,	 decreased	 expression	 of	 tight	 junction	 proteins	 and	 abnormal	 mucus	327	
distribution.	 Absence	 of	 MAIT	 cells	 in	 NOD	 mice	 favors	 gut	 leakiness,	 associated	 with	328	
translocation	of	bacteria	components,	such	as	16S	bacterial	DNA,	from	the	gut	to	peripheral	329	
tissues.	 The	 presence	 of	 bacterial	 DNA	 could	 promote	 T1D	 development	 through	 DC	330	
activation	 via	 TLR	 receptors	 in	 PLN	 and	 increased	 anti-islet	 pathogenic	 T	 cell	 responses.	331	
Altogether,	our	data	support	the	model	in	which	MAIT	cell	deficiency	aggravates	gut	mucosa	332	
alterations,	 thereby	 promoting	 T1D	 development.	 These	 data	 are	 reminiscent	 of	 recent	333	





immune	system.	Their	abundance	and	activation	status	 (CD69,	cytokine	production)	 in	 the	337	






the	 pancreas	 of	 NOD	mice	 and	 their	 production	 of	 GzB	 and	 IFN-γ.	 These	 data	 lead	 us	 to	342	
propose	 that	MAIT	 cells	 are	at	 the	 crossroad	between	gut	mucosa,	 inflammation	and	T1D	343	









We	thank	all	 the	children	and	 their	parents,	 the	adult	patients,	 their	physicians,	 the	nurse	351	
and	the	technical	staff	who	helped	for	this	study.	We	thank	Cécile	Godot,	Annabelle	Voltine	352	
and	Magalie	Viaud	from	Necker	hospital	for	help	in	children	recruitment	and	administrative	353	
tasks.	 We	 also	 thank	 Li	 Yu,	 Sandrine	 Olivre	 for	 technical	 help,	 Amine	 Toubal	 for	 critical	354	
reading	of	the	manuscript,	Franck	Letourneur	for	technical	help	for	16S	analysis,	the	mouse	355	
facility,	Cybio	and	HistIM	facility	from	Cochin	Institute,	Gérard	Eberl	from	Institut	Pasteur	for	356	
the	 RORγt-GFP	 BAC,	 the	 National	 Institutes	 of	 Health	 tetramer	 core	 facility	 for	 NRP-V7	357	
tetramer,	 Hélène	 Fohrer-Ting	 for	 help	 to	 use	 SPICE	 software,	 Angela	 Stabilini	 from	 San	358	
Raffaele,	Milano,	 Italy,	 for	 technical	 help	 and	 Raphael	 Porcher	 and	Moussa	 Laanani	 from	359	
Hôtel	Dieu,	Paris,	France	for	help	to	statistical	analyses,	Paris.	Type	1	Diabetes	TrialNet	is	a	360	
clinical	trials	network	funded	by	the	National	Institutes	of	Health	(NIH)	through	the	National	361	
Institute	 of	 Diabetes	 and	Digestive	 and	 Kidney	Diseases	 (NIDDK),	 the	National	 Institute	 of	362	
Allergy	 and	 Infectious	 Diseases	 (NIAID),	 the	 Eunice	 Kennedy	 Shriver	 National	 Institute	 of	363	
Child	Health	and	Human	Development	(NICHD),	the	National	Center	for	Research	Resources	364	
(NCRR),	 the	 Juvenile	Diabetes	Research	Foundation	 International	 (JDRF),	and	the	American	365	
Diabetes	Association	(ADA).	Work	in	the	R.S.	 lab	is	supported	by	the	“Societé	Francophone	366	
de	 Diabétologie”,	 the	 Foundation	 Bettencourt	 Schueller	 and	 belongs	 to	 the	 Laboratoire	367	
d’Excellence	 consortium	 Revive.	 M.O	 and	 M.D	 are	 supported	 by	 Fondation	 pour	 la	368	
Recherche	 Médicale.	 The	 laboratory	 of	 A.L	 is	 supported	 by	 funds	 from	 INSERM,	 CNRS,	369	
Université	 Paris	 Descartes,	 ANR-11-IDEX-0005-02	 Laboratory	 of	 Excellence	 INFLAMEX,	370	
Fondation	 pour	 la	 Recherche	Médicale	 (n°	 DEQ20140329520)	 and	 EFSD/JDRF/Lilly	 to	 A.L.,	371	
Ministry	of	Research	fellowship	to	O.R.,	Aide	aux	Jeunes	Diabétiques	fellowship	to	I.N.,	the	372	




























































































































































Human	 samples.	 Peripheral	 blood	 samples	were	obtained	 from	control	 children	 and	 from	511	
T1D	children	admitted	in	the	Pediatric	Endocrinology	department	of	Necker	hospital,	Paris,	512	
France	 at	 T1D	 onset	 (i.e.	 within	 10	 days	 from	 first	 insulin	 injection),	 or	 with	 established	513	
disease.	All	control	children,	were	children	presenting	at	the	hospital	for	growth	retardation,	514	
short	 stature	 or	 precocious	 puberty.	 None	 of	 them	 had	 any	 other	 medical	 conditions	 or	515	
history	 of	 autoimmune	 disease.	 Patients	 with	 growth	 retardation	 or	 short	 stature	 were	516	
admitted	for	a	growth	hormone	stimulation	test.	All	of	 them	were	previously	screened	for	517	
coeliac	 disease	 or	 autoimmune	 thyroiditis	 that	 can	 be	 an	 etiology	 of	 short	 stature.	 This	518	
screening	was	negative	for	all	patients.	All	of	these	“control”	children	were	diagnosed	with	519	
idiopathic	growth	hormone	deficiency	or	 idiopathic	short	stature.	Patients	with	precocious	520	
puberty	 didn't	 have	 either	 any	 story	 of	 autoimmune	 disease.	 They	 were	 admitted	 for	 a	521	
gonadotropin-releasing	 hormone	 stimulation	 test	 and	 were	 diagnosed	 with	 idiopathic	522	
central	precocious	puberty.	As	 reported	 in	 the	method	section,	all	 "control"	patients	were	523	
screened	 for	 T1D	 related	 antibodies	 that	 were	 negative.	 Non-inclusion	 clinical	 following	524	
parameters	 contain:	 infection	 during	 the	 admission	 and	 associated	 other	 autoimmune	525	
diseases.	 The	 Ethics	 Committee	 (Comité	 de	 protection	 des	 personnes	 (CPP)	 Ile-de-France)	526	
approved	the	clinical	investigations	and	written	informed	consent	was	obtained	from	all	the	527	
parents.	For	the	Milan	cohort,	peripheral	blood	from	healthy	control	subjects	and	patients	at	528	








approved	 by	 the	 San	 Raffaele	 Hospital	 Ethics	 Committee	 (protocol:	 NHPROTOCOL32803	535	








on	 the	 NOD	 background,	 17	 insulin-dependent	 diabetes	 (Idd)	 loci	 associated	 with	540	
21	
	
susceptibility	 to	 T1D	 have	 been	 checked	 on	 all	 chromosomes.	 MR1
-/-








	 NOD	 littermates	 kept	 in	 co-housed	 cages.	 Transgenic	 ROR-γt-GFP	NOD	mouse	543	
was	 generated	 by	 microinjection	 of	 ROR-γt-GFP	 BAC	 construct
60









a	 glycemia	 >	 200	 mg/Dl	 (ACCU-CHEK,	 Roche).	 This	 study	 was	 approved	 by	 the	 ethics	549	
committee	on	animal	experimentation	CEEA	34	(APAFIS	N°2015102016444419).	550	
	551	
Cell	 preparations.	Human	peripheral	 blood	mono-nucleated	 cells	 (PBMC)	of	 patients	 from	552	
Necker	 Hospital	 were	 isolated	 from	 fresh	 blood	 samples	 by	 Ficoll-Paque	 (Leucosep)	 or	553	
samples	from	San	Raffaele	hospital	were	defrosted	in	RPMI	with	10%	FCS	(Fetal	Cow	Serum).	554	
Mouse	cells	were	prepared	from	different	tissues	as	described	below.	For	Pancreatic	 islets	555	
isolation,	 mice	 were	 sacriﬁced	 and	 pancreas	 was	 perfused	 with	 3	 mL	 of	 a	 collagenase	 P	556	
solution	(0.8	mg/mL,	Roche),	which	was	then	isolated	and	set	free	from	surrounding	tissues	557	
and	 lymph	 nodes.	 Digestion	 of	 the	 pancreas	 was	 performed	 at	 37°C	 for	 10	min	 and	 was	558	
stopped	by	adding	 large	volume	of	cold	5%	FCS	RPMI	before	extensive	washes.	Pancreatic	559	
islets	 were	 then	 puriﬁed	 on	 a	 Ficoll	 discontinuous	 gradient.	 For	 immunoﬂuorescence	560	
analysis,	islets	were	dissociated	with	a	non-enzymatic	cell-dissociation	solution	(Sigma).	For	561	








cell	 suspension	was	 subjected	 to	Percoll	 (GE	Healthcare)	density	gradient	of	40%	and	80%	566	
and	the	interface	between	the	layers	containing	lamina	propria	lymphocytes	were	collected	567	
and	 suspended	 in	 PBS	 containing	 2%	 FCS	 and	 0.1%	 sodium	 azide.	 For	 the	 preparation	 of	568	
mouse	dendritic	 cells	 from	 lymph	nodes	and	 spleen,	mice	were	 sacriﬁced	and	organ	were	569	
cut	 in	 small	 pieces	 and	 then	digested	 at	 37°C	 for	 30	min	with	 2	mL	of	 collagenase	D	 (1.0	570	
22	
	
mg/mL,	 Roche)	 solution.	 Digestion	was	 stopped	 by	 adding	 a	 large	 volume	 of	 cold	 5%	 FCS	571	
RPMI,	and	cells	were	washed	and	filtered	on	cell	strainer	(40	µm,	BD	Falcon)	before	staining.	572	
	573	
Flow	 cytometry	 and	 antibodies.	 Cells	 were	 stained	 in	 PBS	 containing	 5%	 FCS	 and	 0.1%	574	






staining	 was	 always	 performed,	 and	 when	 possible	 due	 to	 the	 number	 of	 PBMC	581	
intracytoplasmic	 staining	 of	 cytokines	 and	 GzB	 after	 PMA-ionomycin	 stimulation	 was	582	
analyzed,	 and	 then	 PBMC	 bcl-2	 expression	 was	 analyzed	 by	 intracytoplasmic	 staining	583	
(without	 stimulation).	 Data	 acquisition	 was	 performed	 using	 BD	 Biosciences	 LSR-Fortessa	584	
cytometer	 or	 FACS	 ARIA	 III	 cytometer	 for	 cells	 from	 patients	 from	 Necker	 hospital	 and	585	
Beckman	Coulter	Gallios	for	cells	from	patients	from	San	Raffaele	hospital.		586	
Staining	 of	 mouse	 cells	 was	 performed	 with	 the	 following	 antibodies:	 TCRβ	 (H57),	 TCR-587	
γδ (GL3),	CD45	(30F11),	CD8α (53−6.7),	CD103	(M290),	CD44	(IM7),	I-Ak	(10-3.6CD45),	CD86	588	
(GL1),	 IL-17A	 (TC11-18H10)	 and	 IFN-γ (XMG1.2) mAbs,	 were	 from	 BD	 Biosciences;	 CD19	589	
(6D5),	CD4	(GK1.5),	CD11b	(M1/70),	PLZF	(9E12),	T-bet	 (4B10),	CD25(PC61),	CD69	(HI-2F3),	590	
CD304	 (3E12),	 and	 CXCR3	 (SA011F11)	mAbs,	 were	 from	 Biolegend;	 CD11c	 (N418),	 CD170	591	
(1RNM44N),	F4/80	(BM8),	ROR-γt	(B2D)	and	FOXP3	(FJK-16s)	mAbs	were	from	eBioscience.	592	
Alpha-Galactosylceramide-CD1d	 tetramer	 was	 prepared	 by	 the	 laboratory	 and	 coupled	 to	593	
streptavidin-BV421	(Biolegend).	NRP-V7	tetramer	(IGRP206-214	(KYNKANVFL)	reactive	T	cell)	594	
and	 TUM	 tetramer	 (TUM	 (KYQAVTTTL)	 reactive	 T	 cell,	 were	 provided	 by	 the	 National	595	
Institutes	 of	Health	 tetramer	 core	 facility.	 Biotinylated	mouse	MR1	 tetramers	 loaded	with	596	
the	 active	 ligand	 (5-OP-RU)	 were	 used	 to	 specifically	 identify	MAIT	 cells	 and	 biotinylated	597	
MR1	tetramers	loaded	with	the	non-activating	ligand	6-formyl-pterin	(6-FP)	were	used	as	a	598	
negative	 control.	 MR1	 tetramers	 were	 coupled	 to	 streptavidin-PE	 (BD	 Biosciences)	 or	599	









obtained	 after	 incubating	 1	 molar	 equivalent	 of	 5-A-RU	 with	 2	 molar	 equivalent	 of	607	
methylglyoxal	 (Sigma-Aldrich).	Co-culture	of	Hela,	expressing	MR1	molecules,	and	PBMC	in	608	












Intra-cellular	 staining.	 For	 human	 Bcl-2	 and	 mouse	 transcription	 factor	 staining,	 after	617	
surface	 staining	 lymphocytes	were	 resuspended	 in	 fixation/permeabilization	 buffer	 (Foxp3	618	
staining	kit	from	eBioscience)	and	incubated	at	4°C	in	the	dark	then,	cells	were	washed	with	619	
PERM	 Wash	 buffer	 (eBioscience)	 and	 labeled	 with	 appropriate	 mAbs.	 For	 cytokine	 and	620	
granzyme	 B	 analysis	 of	 human	 MAIT	 cells,	 PBMC	 obtained	 from	 fresh	 samples,	 were	621	
analyzed	after	stimulation	for	6	h	at	37°C	in	RPMI	medium	supplemented	with	10%	FCS	with	622	
PMA	 (25	 ng/ml)	 and	 ionomycin	 (1	 μg/ml),	 in	 the	 presence	 of	 Brefeldin	 A	 (10	 μg/ml).	 For	623	
cytokine	 staining	 of	mouse	 lymphocytes,	 cells	 were	 stimulated	with	 PMA	 (10	 ng/mL)	 and	624	
ionomycine	(1	µg/mL)	in	the	presence	of	Brefeldin	A	(10	µg/mL)	for	4	h	at	37°C	(all	reagents	625	
from	Sigma-Aldrich)	or	cells	were	stimulated	in	vivo	by	i.v.	injection	of	flagellin	(FLA-PA)	at	3	626	
μg/mouse	2	 h	 before	 analysis,	 as	 previously	 described
61










during	 24	 h	 in	 specifically	 formulated	 DMEM	media	 containing	 5.6	 mM	 glucose,	 2%	 BSA	633	
fraction	 V	 (Roche	 diagnostics),	 50	 μM	 2-mercaptoethanol,	 5	 μg/ml	 transferrin	 (Sigma-	634	




with	 appropriate	 antibodies	 and	 sorted	 by	 FACS-ARIA.	 After	 sorting,	 MAIT	 cells	 were	639	
cultured	 in	complete	medium	containing	RPMI	supplemented	with	10%	FCS,	1%	penicillin/	640	
streptomycin,	 1%	HEPES	and	 supplemented	with	25	ng/mL	 recombinant	human	 IL-7	 (R&D	641	










(Qiagen).	 cDNA	 was	 produced	 using	 the	 Superscript	 III	 reverse	 transcriptase	 (Invitrogen).	652	









transgenic	 Cα-/-	 NOD	 mice.	 T	 cells	 were	 isolated	 from	 splenocytes,	 MLNs	 and	 PLNs	 by	660	
25	
	
depleting	 B	 cells,	 monocytes/macrophages,	 NK	 cells,	 dendritic	 cells,	 erythrocytes,	 and	661	
























Anti-islet	 T	 cell	 response.	 Cells	 from	 mouse	 pancreatic	 islets	 were	 recovered	 and	 then	680	
cultured	for	7	days	in	RPMI	medium	containing	10%	FCS,	1%	penicillin/	streptomycin	and	25	681	





and	MR1+/-	 NOD	mice	 by	measuring	 the	 level	 of	 FITC-dextran	 in	 the	 blood.	 Briefly,	mice	687	





PBS	 to	 determine	 fluorescence	 using	 a	 SPARK	 10M	 (TECAN).	 The	 concentration	 was	691	
determined	using	FITC-dextran	dilutions.	692	
	693	
Alcian	 blue	 staining	 and	 analysis.	 Intestinal	 sections	 (1	 cm	 in	 length)	 of	 ileum	 from	mice	694	
were	 collected	 and	 immediately	 fixed	 in	 4%	 paraformaldehyde	 PBS.	 Paraffin-embedded	695	





MR1+/-	 NOD	mice	 and	DNA	 extraction	was	 performed	 using	 DNeasy	 Blood	 and	 tissue	 Kit	701	
(QIAGEN)	 following	 the	 manufacturer’s	 instructions.	 Quantitative-PCR	 analysis	 was	702	








using	 two-tailed	Mann-Whitney	 test	 and	 signed-rank	Wilcoxon	 test	with	Graph	Pad	Prism.	709	
The	 Kruskal-Wallis	 test	 followed	 by	 the	Wilcoxon	 rank	 sum	 and	 the	 Spearman	 correlation	710	
test	was	 applied	 for	 all	 the	 correlation	 analysis	with	 Software	R.	 	 Corrections	 for	multiple	711	
testing	had	been	performed	on	the	human	results	when	we	compared	flow	cytometry	data	712	
between	the	three	groups	(the	children	with	recent	onset	T1D,	children	with	established	T1D	713	
and	 control	 children);	 Correction	 have	 well	 been	 applied	 after	 using	 the	 signed-rank	714	
Wilcoxon	test	with	an	adjustment	of	the	p-value	with	the	Holm	method	to	take	into	account	715	
the	 fact	 that	 multiple	 testing	 have	 been	 performed.	 A	 factorial	 discriminant	 analysis	 was	716	
performed	using	the	XLSTAT	2016	Software.	A	logistic	regression	model	was	fitted	with	the	717	
PROC	 CANDISC	 software	 (SAS	 version	 p.3)	 then	 a	 backward	 elimination	 procedure	 was	718	





the	 R	 software	 version	 3.2.3.	 For	 mouse	 studies,	 statistical	 analysis	 was	 performed	 with	722	
Prism	 software	 (Graph	 Pad)	 using	 nonparametric	 tests	 two-tailed	 Mann-Whitney	 or	723	




Figure	 1.	 Frequency	 and	 phenotype	 alterations	 of	 blood	MAIT	 cells	 from	 T1D	 children.	
MAIT	cells	were	analyzed	in	blood	from	children	with	recent	onset	T1D	(n=41),	children	with	
established	 T1D	 (n=23),	 as	 compared	 with	 control	 children	 (n=22).	 (a)	 Representative	
staining	 of	MAIT	 cells	 and	MAIT	 cell	 frequency	 among	 T	 lymphocytes.	 (b)	 Representative	
staining	and	frequency	of	MAIT	cells	expressing	different	cell	surface	molecules	(CCR6,	CD56,	
CD69,	CD25,	PD1)	 and	 intracellular	Bcl-2.	 P	 values	were	determined	by	Kruskal-Wallis	 test	





Figure	 2.	 Functional	 alterations	 of	 blood	MAIT	 cells	 from	 T1D	 children.	MAIT	 cells	 were	
analyzed	in	blood	from	children	with	recent	onset	T1D	(n=25)	and	children	with	established	
T1D	 (n=18),	 as	 compared	 with	 control	 children	 (n=18).	 (a)	 Representative	 intracellular	
staining	 of	MAIT	 cells	 for	 cytokines	 and	GzB	 after	 PMA/ionomycin	 stimulation	 and	 graphs	
showing	 the	 frequency	 of	 MAIT	 cells	 producing	 cytokines	 and	 GzB.	 P	 values	 were	
determined	by	Kruskal-Wallis	test	followed	by	the	Wilcoxon	rank	sum	test	adjusted	with	the	
Holm	method.	 (b)	Multi-parametric	 analysis	of	 the	 frequency	of	MAIT	 cells	 expressing	 the	
different	combination	of	 the	 five	 intracellular	molecules:	GzB,	 IFN-γ,	TNF-α,	 IL-17	and	 IL-4.	
Threshold	for	representation	is	cell	frequency	>0.36%	of	MAIT	cells.	Note	that	data	for	IL-4	
are	 not	 shown	 because	 IL-4	 is	 expressed	with	 other	 cytokines	 and	 the	 frequency	 of	 each	













blood	 MAIT	 cells	 expressing	 GzB	 after	 PMA/Ionomycin	 stimulation.	 P	 values	 were	
determined	 by	 Spearman	 test.	 (b)	 EndoC-βH1	 cells	 were	 cultured	 O.N.	 with	 or	 without	
cytokines.	Cells	were	stained	to	analyze	MR1	cell	surface	expression	by	flow	cytometry	(n=4)	
or	directly	lysated	to	analyze	the	relative	quantity	of	MR1	mRNA	by	RT	q-PCR	(n=7).	For	MR1	
cell	 surface	expression	MFI	±	SEM	was	 indicated	 for	each	groups	and	 for	q-PCR,	 statistical	
analysis	was	performed	by	 two-tailed	Mann	Whitney	 test,	P-value	was	 indicated	on	graph	
and	bar	represent	mean	±	SEM.	(c-e)	Induction	of	EndoC-βH1	cell	apoptosis	by	MAIT	cells	in	
co-culture	 in	presence	of	MAIT	cell	 ligand	(5-OP-RU).	MAIT	cells	 from	healthy	donors	were	
sorted	 and	 cultured	with	 IL-7	 during	 48h.	 EndoC-βH1	 cells	were	 cultured	with	 or	without	
cytokines	during	24h.	Then,	MAIT	cells	and	EndoC-βH1	cells	were	co-cultured	for	24h	at	1:1	
ratio	 with	 different	 doses	 of	 5-OP-RU.	 (c)	 Representative	 FACS	 plots	 of	 (d)	 EndoC-βH1	
apoptosis	by	MAIT	cells	at	different	doses	of	5-OP-RU	[0-1000	nmol/L]	(n=4).	Blocking	MR1	
mAb	 was	 added	 when	 indicated.	 Statistical	 analysis	 were	 performed	 by	 two-tailed	Mann	
Whitney	 test,	 P-values	were	 indicated	 on	 each	 graph	 and	 bar	 represent	mean	 ±	 SEM.	 (e)	
Activation	and	degranulation	of	MAIT	cells	in	presence	or	not	of	ligand	and	anti-MR1	(n=2).		
	
Figure	 4.	 MAIT	 cell	 characteristics	 in	 patients	 at	 different	 disease	 stages.	 (a)	 MAIT	 cell	
staining	of	 surface	and	 intracellular	molecules	performed	with	PBMC	from	fifteen	children	





the	 T1D	 phenotype.	 (d)	 FACS	 Analysis	 of	 MAIT	 cell	 frequency	 among	 T	 lymphocytes	 and	




Figure	 5.	 Characterization	 of	 MAIT	 cells	 in	 NOD	 and	 C57BL/6	 mice.	 MAIT	 cells	 were	
identified	 using	 mouse	 MR1-5-OP-RU	 tetramer	 and	 MR1-Ac-6-FP	 tetramer	 was	 used	 as	
control.	MAIT	cells	are	defined	as	positive	MR1	tetramer	(5-OP-RU)	and	low	TCRβ	staining.	
Flow	 cytometric	 analysis	 of	 spleen,	 pancreatic	 lymph	 nodes	 (PLN),	 pancreatic	 islets	 and	
ileum	 from	C57BL/6	 and	NOD	mice	 at	 9-12	weeks	 of	 age.	 (a)	 Representative	 dot	 plots	 of	





plots	 of	 CD4	 and	 CD8	 expression	 by	MAIT	 cells	 in	 NOD	mice	 and	 (d)	 graphs	 showing	 the	
proportion	of	MAIT	cell	subsets	in	tissues	from	C57BL/6	and	NOD	mice.	Data	correspond	to	8	
mice	 from	three	 independent	experiments.	Bar	 represent	mean	±	SEM.	 (e)	Representative	
histograms	and	(f)	graphs	showing	CD69,	CD25	and	CD44	expression	on	MAIT	cells	from	NOD	
mice	 (white)	 and	C57BL/6	 (black).	P	 values	were	determined	by	 two-tailed	Mann-Whitney	
test	(statistical	analysis	between	tissues	from	NOD	mice;	C57BL/6	analyses	are	not	shown).	
(g)	Representative	dot	plots	and	(h)	graphs	showing	intracellular	cytokine	(IFN-γ,	TNF-α,	IL-
17A	and	 IL-22)	 staining	of	MAIT	 cells	 in	10	week-old	NOD	mice	 (white)	 and	C57BL/6	mice	
(black),	after	PMA/ionomycin	stimulation.		
	
Figure	6.	MAIT	 cell	 frequencies	and	 function	during	diabetes	development.	 (a)	MAIT	 cell	
frequency	 in	 different	 tissues	 from	 NOD	mice	 at	 three	 stages	 of	 disease	 development	 (6	
weeks,	 16	 weeks,	 and	 diabetic).	 For	 each	 tissue	 at	 least	 6	 mice	 per	 group	 from	 five	
independent	experiments	were	analyzed.	Statistics	were	performed	with	two	tailed	Mann-




	 cells/mice).	 At	 day	 5	 after	 transfer,	 mice	 were	 sacrificed	 and	 islets	 and	 ileum	 were	
analyzed.	 Graphs	 and	 representative	 plots	 of	 the	 frequency	 and	 the	 absolute	 number	 of	
transferred	MAIT	cells	are	shown.	(c-d)	Graphs	showing	the	relative	quantity	of	(c)	GzB,	IFN-γ	
transcripts	 in	MAIT	cells	 from	pancreatic	 islets	and	(d)	 IL-22	and	IL-17A	transcripts	 in	MAIT	
cells	from	ileum	at	three	stages	of	disease	development.	Each	symbol	represents	a	pool	of	
two	mice	and	data	were	obtained	in	two	independent	experiments.	Bars	represent	mean	±	
SEM.	 (e-f)	Cytokine	 intracellular	staining	after	 in	vitro	PMA/ionomycin	stimulation	(e)	or	 in	









pooled	 from	 two	 independent	 experiments.	 (b)	 Cells	 of	 ileal	 tissue	 from	 NOD	mice	 were	
obtained	 and	 analyzed	 by	 RT-qPCR	 at	 two	 stages	 of	 the	 disease	 (10	 weeks	 and	 diabetic	
mice);	 the	 relative	 quantity	 of	 IL-23	 transcript	 is	 shown.	 Data	 are	 pooled	 from	 two	
independent	 experiments.	 (c)	 Intestinal	 gut	 permeability	 was	 measured	 by	 in	 vivo	 FITC-












Figure	 8.	MAIT	 cell	 deficiency	 exacerbates	 diabetes	 development	 and	 alters	 gut	mucosa	





littermates.	 (a)	 Representive	 dot	 plots	 of	 T	 cell	 staining	 with	 MR1-5-OP-RU	 and	 CD1d-α-
Galactosyl	 Ceramide	 tetramers	 of	 splenic	 cells,	 gated	 on	αβT	 cells.	 Numbers	 indicate	 the	
percentage	of	MAIT	and	 iNKT	cells	among	TCRβ cells.	 (b)	Diabetes	 incidence	of	MR1-/-	and	
MR1
+/-
	 mice	 (n=30	 and	 32	 respectively);	 P	 values	 were	 determined	 by	 Gehan-Breslow-
Wilcoxon	 test.	 (c)	 Representative	 dot	 plots	 and	 graphs	 showing	 percentage	 of	 IGRP206-214	










dendritic	 cells	 from	 ileum,	 mesenteric	 (MLN)	 and	 pancreatic	 lymph	 nodes	 (PLN).	
Representative	flow	cytometry	dots	showing	the	gating	strategy,	MHC	class	II	staining,	and	
graphs	 showing	 the	 absolute	 numbers	 of	 this	 DC	 subset,	 the	 frequencies	 and	 absolute	
numbers	 of	 this	 DC	 subset	 expressing	 CD86	 and	 MHC	 class	 II.	 (f)	 Intestinal	 permeability	
measured	 by	 FITC-dextran	 assay.	 (g)	 Occludin,	 mucin-2	 and	 claudin-4	 mRNA	 levels	 in	
epithelial	cells	 from	ileum.	 (h)	Representative	photographs	of	Alcian	blue	staining	of	 ileum	
section	 and	 graph	 showing	 the	mean	 intensity	 of	 the	 staining	 in	Goblet	 cells.	 (i)	 Absolute	
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Recent onset T1D children !
Established T1D children !
Supplementary	Figure	1	(a)	Number	of	blood	MAIT	cells	among	ﬁve	millions	of	PBCM	from	children	with	recent	
onset	T1D	(n=35),	children	with	established	T1D	(n=23)	as	compared	with	control	children	(n=22).	(b)	Frequency	
of	 the	 subpopulaNon	 CD8+	 and	 DN	 MAIT	 cells	 among	 T	 lymphocytes	 from	 children	 with	 recent	 onset	 T1D	











































































































Supplementary	Figure	2	 (a)	Frequency	of	Vα7.2+CD161-	cells	among	T	 lymphocytes	and	 (b)	 frequency	of	 the	
CD4+	and	CD8+	T	lymphocytes	from	children	with	recent	onset	T1D	(n=41),	children	with	established	T1D	(n=23)	
as	 compared	 with	 control	 children	 (n=22).	 No	 signiﬁcaNve	 diﬀerences	 as	 determined	 by	 Kruskal-Wallis	 test	
followed	by	the	Wilcoxon	rank	sum	test	adjusted	with	the	Holm	method.		
Control children !
Recent onset T1D children !
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% of PD1+ MAIT cells!
r = 0.37!
P = 0.028!
Supplementary	 Figure	 4	CorrelaNon	 between	 frequency	 of	MAIT	 cells	 expressing	GzB	 and	 frequency	 of	MAIT	 cells	
among	 T	 lymphocytes	 from	 children	 with	 recent	 onset	 T1D	 (n=22).	 CorrelaNon	 between	 frequency	 of	 MAIT	 cells	
expressing	CCR6	and	frequency	of	MAIT	cells	expressing	GzB	(n=22).	P	values	were	determined	by	Spearman	test.	
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r = -0.51!
P = 0.016!
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P = 0.013!







































































































































































































Supplementary	 Figure	 6.	 CD44	 expression	 on	 MAIT	 cell	 subsets	 in	 NOD	 and	 C57BL/6	 mice.	 (a)	 RepresentaNve	

























































































































































cytokine	 staining	 of	MAIT	 cells	 from	 islets	 and	 ileum	 of	 10	week-old	 NOD	mice.	MAIT	 cells	 are	 analyzed	 aaer	 PMA/
ionomycin	sNmulaNon	and	labeled	with	MR1-5-OP-RU	tetramer	and	then	ﬁxed	and	permeabilized	before	staining	with	
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Supplementary	 Figure	 9.	MAIT	 cell	 expression	 of	 PLZF,	 ROR-γt	 and	 T-bet.	 Expression	 of	 the	 transcripNon	 factors	
PLZF,	ROR-γt	and	T-bet	by	MAIT	cells	from	the	spleen,	PLNs,	pancreaNc	islets	and	ileum	from	10	week-old	NOD	mice.	
RepresentaNve	dot	plots	with	indicated	percentage	of	PLZF,	ROR-γt	and	T-bet	expression	in	MAIT	and	iNKT	cells	from	
























































































































































































 5.4 a 
NOD genetic background 
B6 genetic background 
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type	 1	 diabetes.	 MAIT	 cells	 recognize	 bacterial	 metabolites	 and	 changes	 of	 gut	 microbiota	 are	
associated	with	diabetes	development.	 In	 the	 intesNne	of	10	week-old	NOD	 females,	MAIT	 cells	
produce	IL-17A	and	IL-22,	two	key	cytokines	involved	in	the	maintenance	of	gut	mucosa	integrity.	
(1)	 During	 disease	 progression,	 the	 producNon	 of	 both	 cytokines	 by	 ileal	 MAIT	 cell	 decreases,	
thereby	 dampening	 their	 protecNve	 role.	 (2)	Moreover	 in	MR1-/-	 NOD	mice	 lacking	MAIT	 cells	
several	abnormaliNes	are	observed	in	the	gut	mucosa:	increased	gut	permeability,	decreased	Nght	
juncNon	 protein	 expression,	 alteraNon	 of	 mucus	 producNon	 and	 distribuNon,	 and	 increased	
lymphocyte	 inﬁltraNon	 in	 the	 lamina	propria.	 (3)	This	defecNve	 intesNnal	barrier	 could	 favor	 the	
translocaNon	of	 bacterial	 ligands	 such	 as	 lipopolysaccharide	 (LPS),	DNA,	 pepNdoglycan	 (PG)	 that	
could	 promote	 dendriNc	 cell	 acNvaNon	 as	 evidenced	 by	 their	 increase	 MHC	 class	 II	 and	 CD86	
upregulaNon	 in	 pancreaNc	 lymph	nodes.	 (4)	 Subsequently,	 these	DC	 can	 acNvate	 autoreacNve	 T	
cells	recognizing	beta-cell	anNgen.	(5)	These	anN-islet	T	cells	migrate	to	the	pancreas	where	they	
produce	IFN-g	and	thus	destroy	beta	cells.	This	mechanism	highlights	the	protecNve	role	of	MAIT	
cells	 against	 T1D	 development.	 (6)	 However,	 MAIT	 cells	 can	 also	 parNcipate	 to	 beta-cell	 death	
through	their	producNon	of	IFN-g	and	granzyme	B	(GzB).	(7)	InteresNngly,	in	T1D	paNents	there	is	
an	increase	producNon	of	GzB	by	blood	MAIT	cells.	While	MAIT	cells	exert	dual	funcNon,	analysis	of	
mouse	models	reveal	the	dominant	protecNve	role	of	MAIT	cells	in	T1D.	
		
